Cargando…

Platelet-rich plasma in patients affected with Peyronie’s disease

OBJECTIVES: The objective of our study is to discover and evaluate the effects of repeated intralesional injections inside the tunica albuginea of platelet-rich plasma (PRP) in the treatment of Peyronie’s disease (PD). METHODS: As part of a prospective study over 12 months from February 2020 until F...

Descripción completa

Detalles Bibliográficos
Autores principales: Achraf, Chatar, Abdelghani, Pr Ammani, Jihad, Pr El Anzaoui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208162/
https://www.ncbi.nlm.nih.gov/pubmed/37234679
http://dx.doi.org/10.1080/2090598X.2022.2135284
_version_ 1785046613165604864
author Achraf, Chatar
Abdelghani, Pr Ammani
Jihad, Pr El Anzaoui
author_facet Achraf, Chatar
Abdelghani, Pr Ammani
Jihad, Pr El Anzaoui
author_sort Achraf, Chatar
collection PubMed
description OBJECTIVES: The objective of our study is to discover and evaluate the effects of repeated intralesional injections inside the tunica albuginea of platelet-rich plasma (PRP) in the treatment of Peyronie’s disease (PD). METHODS: As part of a prospective study over 12 months from February 2020 until February 2021, on Sixty-five patients with Peyronie’s disease, and penile curvature between 25 and 45°. Patients were stratified into two groups, the first with a curvature between 25 and 35° and the second between 35 and 45°. Gathered data included patient-demographics, Injection technique, outcomes: both quantitative (curvature assessments) and qualitative (state of erectile function, pain during intercourse), and complications. RESULTS: Patients in both groups received an average of 6.1 injections of PRP during the study period. Angulation was significantly improved in both groups an average final improvement of 16.88° (SD = 3.35) (p < 0.001) in the first group and 17.27° (SD = 4.22) (p < 0.001) in the second group. Pain during sex decreased from 70.7% to 34.25%, and 55.5% of patients had easier sexual intercourse. CONCLUSIONS: The positive results of our series of treatment for Peyronie’s disease by injection of platelet-rich plasma are encouraging both methodologically (simplicity) and clinical (safety and efficacy) as well as patient satisfaction.
format Online
Article
Text
id pubmed-10208162
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-102081622023-05-25 Platelet-rich plasma in patients affected with Peyronie’s disease Achraf, Chatar Abdelghani, Pr Ammani Jihad, Pr El Anzaoui Arab J Urol Andrology and Sexual Medicine OBJECTIVES: The objective of our study is to discover and evaluate the effects of repeated intralesional injections inside the tunica albuginea of platelet-rich plasma (PRP) in the treatment of Peyronie’s disease (PD). METHODS: As part of a prospective study over 12 months from February 2020 until February 2021, on Sixty-five patients with Peyronie’s disease, and penile curvature between 25 and 45°. Patients were stratified into two groups, the first with a curvature between 25 and 35° and the second between 35 and 45°. Gathered data included patient-demographics, Injection technique, outcomes: both quantitative (curvature assessments) and qualitative (state of erectile function, pain during intercourse), and complications. RESULTS: Patients in both groups received an average of 6.1 injections of PRP during the study period. Angulation was significantly improved in both groups an average final improvement of 16.88° (SD = 3.35) (p < 0.001) in the first group and 17.27° (SD = 4.22) (p < 0.001) in the second group. Pain during sex decreased from 70.7% to 34.25%, and 55.5% of patients had easier sexual intercourse. CONCLUSIONS: The positive results of our series of treatment for Peyronie’s disease by injection of platelet-rich plasma are encouraging both methodologically (simplicity) and clinical (safety and efficacy) as well as patient satisfaction. Taylor & Francis 2022-10-25 /pmc/articles/PMC10208162/ /pubmed/37234679 http://dx.doi.org/10.1080/2090598X.2022.2135284 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Andrology and Sexual Medicine
Achraf, Chatar
Abdelghani, Pr Ammani
Jihad, Pr El Anzaoui
Platelet-rich plasma in patients affected with Peyronie’s disease
title Platelet-rich plasma in patients affected with Peyronie’s disease
title_full Platelet-rich plasma in patients affected with Peyronie’s disease
title_fullStr Platelet-rich plasma in patients affected with Peyronie’s disease
title_full_unstemmed Platelet-rich plasma in patients affected with Peyronie’s disease
title_short Platelet-rich plasma in patients affected with Peyronie’s disease
title_sort platelet-rich plasma in patients affected with peyronie’s disease
topic Andrology and Sexual Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208162/
https://www.ncbi.nlm.nih.gov/pubmed/37234679
http://dx.doi.org/10.1080/2090598X.2022.2135284
work_keys_str_mv AT achrafchatar plateletrichplasmainpatientsaffectedwithpeyroniesdisease
AT abdelghaniprammani plateletrichplasmainpatientsaffectedwithpeyroniesdisease
AT jihadprelanzaoui plateletrichplasmainpatientsaffectedwithpeyroniesdisease